US-Made Drugs: Preferential Treatment in Medicare and Medicaid Programs.
This Act establishes a minimum 7-year demonstration program to prioritize drugs manufactured in the United States within federal health programs (Medicare, Medicaid, CHIP). For citizens, this could lead to lower out-of-pocket costs for certain medications and aims to strengthen the domestic supply chain for critical drugs, reducing reliance on foreign sources.
Key points
Lower Patient Costs: The program tests tools like reduced patient cost-sharing for US-manufactured drugs.
Supply Chain Security: Preference is given to companies that maintain high emergency reserves and diverse sourcing, mitigating the risk of drug shortages.
Domestic Manufacturing Support: Drugs must be made in the US by companies adhering to strict requirements regarding transparency and supply chain resilience.
Expired
Citizen Poll